Biobanks Market – Analysis and Forecast 2025-2035

The global Biobanks Market is projected to exceed USD 77 billion by 2032. Biobanks act as repositories for biological fluids and tissue samples, serving as critical tools for studying genetic and tissue dynamics, which in turn support the development of advanced therapies such as precision medicine, gene therapy, regenerative medicine, and oncology. The growing importance of research and development in driving innovations across genomics and personalized treatment approaches has significantly enhanced the role of the Biobanks Market. Biobanks are increasingly being utilized in drug discovery, understanding chronic illnesses, identifying treatment strategies, and studying genetic variations in detail. Rising chronic disease prevalence, fueled by unhealthy lifestyles and an expanding geriatric population, is driving demand for effective treatment solutions, with biobanking playing a central role. For instance, Qatar expanded its research capabilities by positioning Qatar Biobank as a member of the Biobanking and BioMolecular Resources Research Infrastructure – European Research Infrastructure Consortium, enabling global resource sharing for health advancements.

Companies in the Biobanks Market are actively pursuing strategies such as mergers, acquisitions, collaborations, and long-term agreements to strengthen their global presence. A notable example is BioLifeSolutions, which in 2021 acquired Stirling Ultracold, a company specializing in ultra-low temperature freezers, and Sexton Biotechnologies, a provider of cell and gene therapy manufacturing solutions. These acquisitions advanced BioLifeSolutions’ position in the preservation and supply of cell therapy tools. Additionally, continuous R&D investments toward innovative products supporting chronic disease management are driving market growth across multiple levels.

According to CXOs and primary research, the COVID-19 pandemic had a positive impact on the Biobanks Market. The urgent need for vaccine and therapeutic development accelerated drug discovery, emphasizing the use of patient samples for rigorous testing to better understand the virus. Plasma repositories and tissue banks became critical resources for transfusion therapies, where plasma from recovered patients was used to help treat infected individuals by transferring antibodies. The pandemic highlighted the significance of genetics in immune response, spurring further R&D in genomics and unlocking new opportunities for the Biobanks Market.

The Biobanks Market is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Among these, Asia-Pacific is expected to witness the fastest growth, followed by Europe, North America, Latin America, and the Middle East & Africa. Key factors driving Asia-Pacific’s market potential include a rising geriatric population, the growing burden of chronic diseases, the adoption of advanced therapies such as precision medicine and regenerative medicine, and the presence of leading industry players in the region. Major companies operating within the Biobanks Market include Brooks Life Sciences, BioLifeSolutions Inc., BioCision, Cell&Co BioServices, Hamilton Company, Thermo Fisher Scientific Inc., Tecan Trading AG, TTP Labtech, Taylor-Wharton, and VWR International LLC.

Click here to read complete article